## OIE Reference Laboratory Reports Activities Activities in 2021

## This report has been submitted : 2022-01-19 17:17:21

| Name of disease (or topic) for which<br>you are a designated OIE Reference<br>Laboratory: | Newcastle disease  |  |  |
|---|--|--|--|
| Address of laboratory:  | OIE Reference Laboratory for Avian Influenza disease Istituto<br>Zooprofilattico Sperimentale delle Venezie (IZSVe) Viale<br>dell'Università 10 – 35020 Legnaro (PD) - Italy   |  |  |
| Tel.:   | +39-049 808 4381   |  |  |
| Fax:  | +39-049 808 4360   |  |  |
| E-mail address:   | imonne@izsvenezie.it   |  |  |
| Website:  | www.izsvenezie.it  |  |  |
| Name (including Title) of Head of<br>Laboratory (Responsible Official):                   | Calogero Terregino, Head of the EU/National Reference<br>Laboratory for Al/NDV. Director of the Research and<br>Development Department/acting Director of the Specialized<br>Virology and Experimental Research Unit (IZSVe) |  |  |
| Name (including Title and Position)<br>of OIE Reference Expert:                           | Isabella Monne, DVM PhD, Head of the Viral genomics and transcriptomics Laboratory, Division of Research and Innovation  |  |  |
| Which of the following defines your laboratory? Check all that apply:                     | Governmental   |  |  |

# ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test                          | Indicated in OIE<br>Manual<br>(Yes/No) | Total number of test performed last year |                 |
|--|--|--|-----------------|
| Indirect diagnostic tests                |  | Nationally                               | Internationally |
| Haemoagglutination inhibition (HI)       | Yes                                    | 740                                      | 16              |
| ELISA                                    | Yes                                    | 145                                      | 0               |
| Direct diagnostic tests                  |  | Nationally                               | Internationally |
| Virus Isolation                          | Yes                                    | 41                                       | 3               |
| RRT/RT-PCR                               | Yes                                    | 575                                      | 992             |
| Sequencing of F gene                     | Yes                                    | 63                                       | 21              |
| ICPI - Intracerebral Pathogenicity Index | Yes                                    | 9  | 1               |
| WGS - Whole Genome Sequencing            | Yes                                    | 0  | 67              |

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

| Type of<br>reagent<br>available | Related<br>diagnostic<br>test  | Produced/<br>provide | Amount<br>supplied<br>nationally<br>(ml, mg) | Amount<br>supplied<br>internationally<br>(ml, mg) | No. of<br>recipient<br>OIE<br>Member<br>Countries | Region of recipients  |
|---------------------------------|--------------------------------|----------------------|--|---|---|---|
| Control<br>positive<br>antigens | HI<br>serological<br>test      | 4431/329<br>ml       | 94 ml  | 235 ml  | 19  | <ul> <li>□ Africa</li> <li>□ Americas</li> <li>□ Asia and</li> <li>Pacific</li> <li>□ Europe</li> <li>□ Middle</li> <li>East</li> </ul> |
| Control<br>positive<br>sera     | HI/AGID<br>serological<br>test | 927/399 ml           | 201 ml                                       | 198 ml  | 17  | <ul> <li>☑ Africa</li> <li>☑ Americas</li> <li>☑ Asia and</li> <li>Pacific</li> <li>☑ Europe</li> <li>☑ Middle</li> <li>East</li> </ul> |
| Control<br>negative<br>serum    | HI<br>serological<br>test      | 1280/428<br>ml       | 91 ml  | 337 ml  | 15  | <ul> <li>△Africa</li> <li>△Americas</li> <li>△Asia and</li> <li>Pacific</li> <li>△Europe</li> <li>Middle</li> <li>East</li> </ul>       |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

# ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

# ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

| Name of OIE Member Country seeking assistance | Date (month)            | No. samples<br>received for<br>provision of<br>diagnostic support | No. samples received<br>for provision of<br>confirmatory<br>diagnoses |
|---|-------------------------|---|---|
| ALBANIA                                       | June                    | 0   | 1   |
| AUSTRIA                                       | December                | 0   | 13  |
| BELGIUM                                       | Мау                     | 0   | 4   |
| IRELAND                                       | February, April, August | 0   | 5   |
| LITHUANIA                                     | Мау                     | 0   | 3   |
| NIGERIA                                       | March, September        | 719   | 64  |
| NIGER   | March                   | 0   | 5   |
| NORWAY  | February                | 0   | 14  |
| ROMANIA                                       | March, May              | 0   | 3   |
| SLOVENIA                                      | February                | 0   | 3   |
| SLOVAKIA                                      | February                | 0   | 2   |
| SWITZERLAND                                   | June                    | 0   | 1   |
| UNITED KINGDOM                                | January                 | 0   | 1   |

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

| Name of the OIE Member<br>Country receiving a<br>technical consultancy | Purpose  | How the advice was provided  |
|--|--|------------------------------|
| IRELAND  | Clarifications on the requirements for testing NDV<br>under the new AHL: laboratory methods;<br>vaccination on poultry and possible interference<br>with the serological testing for AI surveillance | Remote assistance<br>(email) |

## **ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

| Title of the<br>study  | Duration | Purpose of the study   | Partners (Institutions)  | OIE Member<br>Countries<br>involved<br>other than<br>your<br>country |
|--|----------|--|--|--|
| LIDISKI Project:<br>Improving the<br>livelihoods of<br>smallholder<br>livestock<br>farmers in<br>Nigeria | 4 years  | Improving<br>surveillance and<br>control of Peste des<br>petits ruminants<br>(PPR) and Newcastle<br>Disease (ND), the<br>two main diseases<br>affecting the<br>livestock of<br>smallholder farmers<br>in North of Nigeria. | Centre de coopération<br>Internationale en Recherche<br>Agronomique pour le<br>Développement – CIRAD (France),<br>IZSVE (Italy), Ikore (Nigeria),<br>National Veterinary Institute<br>(Nigeria), National Agricultural<br>Extension and Research Liaison<br>Services -NAERLS (Nigeria), The<br>Federal Ministry of Agriculture and<br>Rural Development – FMARD<br>(Nigeria), International Livestock<br>Research Institute – ILRI (Kenya),<br>OIE-World Organisation for Animal<br>Health | FRANCE<br>ITALY<br>KENYA<br>NIGERIA                                  |

# ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

°Collection and analysis of the information generated by epidemiological and genetic surveillance in domestic and wild birds in Italy. ° Collection and analysis of the information generated by epidemiological and genetic surveillance in rural poultry in Nigeria.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

#### If the answer is yes, please provide details of the data collected:

National Information Systems: regular reporting of epidemiological data to the Ministry of Health and the European Commission. Reporting results of molecular, epidemiological and diagnostic analyses to EU NRLs by email and through Mattermost, a flexible, open source messaging platform that enables secure team collaboration and enhances an active collaboration between veterinary/public health laboratories and scientists from the European Union (EU). This allows rapid dissemination of Newcastle disease updates when needed.

## **13.** What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1

1. Twabela, A.T., Nguyen, L.T., Masumu, J., Mpoyo, P., Mpiana, S., Sumbu, J., Okamatsu, M., Matsuno, K., Isoda, N., Zecchin, B., Monne, I., & Sakoda, Y. (2021). A New Variant Among Newcastle Disease Viruses Isolated in the Democratic Republic of the Congo in 2018 and 2019. Viruses, 13, 10.3390/v13020151.

b) International conferences: 1

EURL team at IZSVe

Presentations from the 27th Annual Meeting of the National Reference Laboratories for Avian Influenza and Newcastle Disease of European Union Member States https://www.izsvenezie.com/reference-laboratories/avian-influenza-newcastle-disease/workshops/

c) National conferences: 1

Updates on avian Influenza and Newcastle Disease from the National Reference Centre (October 2021) https://www.izsvenezie.it/documenti/formazione/corsi-convegni/2021/2021-10-26-aggiornamenti-influenza-aviaria /programma.pdf

https://www.izsvenezie.it/formazione/corsi-e-convegni/archivio-corsi-e-convegni/

d) Other:

(Provide website address or link to appropriate information) 3 IZSVE website, OIE & FAO activities: https://www.izsvenezie.com/reference-laboratories/avian-influenza-newcastle-disease/oie-fao-activities/

IZSVE website, European Union Reference Laboratory (EURL) for Avian Influenza and Newcastle Disease: http://www.izsvenezie.com/reference-laboratories/avian-influenza-and-newcastle-disease/

Lidiski project - Improving the livelihoods of smallholder livestock farmers in Nigeria http://www.lidiski.org/ https://www.youtube.com/watch?v=Gp1aa03u4nY&feature=emb\_logo https://www.lidiski.org/distinctive-symptoms-of-newcastle-disease/ https://www.lidiski.org/newcastle-disease-control-and-the-effectiveness-of-biosecurity/

#### ToR 7: To provide scientific and technical training for personnel from OIE Member Countries To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 0

b) Seminars: 100

c) Hands-on training courses: 1

d) Internships (>1 month): 0

| Type of technical<br>training provided (a, b,<br>c or d) | Country of origin of the expert(s) provided with training                        | No. participants from the corresponding country |
|--|--|---|
| b  | 28 EU countries and 8 non EU countries (detailed information available at IZSVe) | 100   |
| с  | Nigeria  | 1   |

## **ToR 8: To maintain a system of quality assurance, biosafety and biosecurity** *relevant for the pathogen and the disease concerned*

15. Does your laboratory have a Quality Management System?

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |
|-----------------------------------|---|
| ISO 17025                         | A_20_certificato ISO 17025.pdf          |
| ISO 17043                         | B_certificato-ISO-17043-aqua.pdf        |

16. Is your quality management system accredited?

| Test for which your laboratory is accredited   | Accreditation body                         |
|--|--|
| Detection of antibodies to Newcastle disease virus (NDV) by haemagglutination inhibition test  | ACCREDIA – Italian Accreditation<br>System |
| Isolation and characterization of Newcastle disease viruses using SPF embryonated chicken eggs and haemagglutination inhibition test | ACCREDIA – Italian Accreditation<br>System |
| Detection of APMV-1 virus (Avian Paramyxovirus Type 1) by RT-<br>PCR   | ACCREDIA – Italian Accreditation<br>System |
| APMV-1 virus (Avian Paramyxovirus Type 1) sequence analysis  | ACCREDIA – Italian Accreditation<br>System |
| Detection of APMV-1 virus (Avian Paramyxovirus Type 1) by real time RT-PCR   | ACCREDIA – Italian Accreditation<br>System |
| Proficiency testing provider   | ACCREDIA – Italian Accreditation<br>System |

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

#### ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

# ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

| Purpose of the proficiency tests: <sup>1</sup>                                 | Role of your<br>Reference<br>Laboratory<br>(organiser/<br>participant) | No. participants                                   | Participating OIE Ref. Labs/ organising OIE<br>Ref. Lab.   |
|--|--|--|--|
| European<br>Proficiency Test on<br>Avian Influenza<br>and Newcastle<br>Disease | Organiser  | 40 (26 from EU<br>and 14 from non<br>EU countries) | <ul> <li>Friedrich Loeffler Institute Federal<br/>Research Institute for Animal Health Institute<br/>of Diagnostic Virology (Germany);</li> <li>NRL for<br/>Avian Influenza and Newcastle Disease<br/>Federal State-Financed Institution "Federal<br/>Centre for Animal Health" (FGBI "ARRIAH")<br/>(Russia)</li> <li>Animal and Plant Health Agency<br/>Weybridge (UK) (detailed Information<br/>available at IZSVe)</li> </ul> |

<sup>1</sup> validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only OIE Reference Lab. designated for disease)

## ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <u>http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing</u> see point 1.3

| Purpose for inter-laboratory test comparisons <sup>1</sup>                         | No. participating<br>laboratories | Region(s) of participating OIE<br>Member Countries                   |
|--|-----------------------------------|--|
| National Proficiency Test for Avian Influenza and<br>Newcastle Disease (organiser) | 20                                | ■Africa<br>■Americas<br>■Asia and Pacific<br>■Europe<br>■Middle East |

## ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

| Kind of consultancy  | Location                   | Subject (facultative)  |
|--|----------------------------|--|
| Webinar:One expert participated as<br>invited speaker with the contribution<br>titled "Organisation of activities of<br>Reference Laboratories in EU countries". | Legnaro,<br>Padova (Italy) | Webinar "The Role of Veterinary Reference<br>Laboratories, and Guidelines in Veterinary<br>Education" held on 13th May 2021, organised<br>by OIE – EEC Eurasian Economic Commission. |

25. Additional comments regarding your report: